Inducible regulation of GDNF expression in human neural stem cells

Science China Life Sciences

Volumn 56, Issue 1, 2013, Pages 32-39

  Wang, ShuYan ^a   Ren, Ping ^a   Guan, YunQian ^a   Zou, ChunLin ^a   Fu, LinLin ^a   Zhang, Yu ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

GDNF; lentivirus vectors; neural stem cells; tetracycline operator

Indexed keywords

LENTIVIRUS;

EID: 84872309249     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-012-4424-6     Document Type: Article

References (20)

1. Lin L F, Doherty D H, Lile J D, et al. GDNF: a glial cell line-derived neurotrophicn factor midbrain dopaminergic neurons. Science, 1993, 260: 1130-1132.
2. Kordower J H, Emborg M E, Bloch J, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science, 2000, 290: 767-773.
3. Gill S S, Patel N K, Hotton G R, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med, 2003, 9: 589-595.
4. Svendsen C N, Clarke D J, Rosser A E, et al. Survival and differentiation of rat and human epidermal growth factor-responsive precursor cells following grafting into the lesioned adult central nervous system. Exp Neurol, 1996, 137: 376-388.
5. Carpenter M K, Cui X, Hu Z Y, et al. In vitro expansion of a multipotent population of human neural progenitor cells. Exp Neurol, 1999, 158: 265-278.
6. Svendsen C N, Caldwell L M A, Shen J, et al. Long-term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson's disease. Exp Neurol, 1997, 148: 135-146.
7. Klein S M, Behrstock S, McHugh J, et al. Neurospheres modified to produce glial cell line-derived neurotrophic factor increase the survival of transplanted dopamine neurons. J Neurosci Res, 2002, 69: 955-965.
8. Klein S M, Behrstock S, McHugh J, et al. GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum Gene Ther, 2005, 16: 509-521.
9. Behrstock S, Ebert A, McHugh J, et al. Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates. Gene Ther, 2006, 13: 379-388.
10. Georgievska B, Kirik D, Bjorklund A, et al. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp Neurol, 2002, 177: 461-474.
11. Gossen M, Freundlieb S, Bender G, et al. Transcriptional activation by tetracyclines in mammalian cells. Science, 1995, 268: 1766-1769.
12. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA, 1992, 89: 5547-5551.
13. Koponen J K, Kankkonen H, Kannasto J, et al. Doxycycline-regulated lentiviral vector system with a novel reverse transactivator rtTA2S-M2 shows a tight control of gene expression in vitro and in vivo. Gene Ther, 2003, 10: 459-466.
14. Zhou B Y, Ye Z H, Gao P, et al. Inducible and reversible transgene expression in human stem cells stably transduced by novel lentiviral vectors. Stem cells, 2006, 25: 779-789.
15. Kirik D, Georgievska B, Bjorklund A, et al. Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat Neurosci, 2004, 7: 105-110.
16. Judith F M, Josh R F, Wolfram K H, et al. Kruppel-associated boxes are potent transcriptionalrepression domains. Proc Natl Acad Sci USA, 1994, 91: 4509-4513.
17. Deuschle U, Meyer W K, Thiesen H J. Tetracycline-reversible silencing of eukaryotic promoters. Mol Cell Biol, 1995, 15: 1907-1914.
18. Moosmann P, Georgiev O, Thiesen H J, et al. Silencing of RNA polymerases II and III-dependent transcription by the KRAB protein domain of KOX1, a Krüppel-type zinc finger factor. Biol Chem, 1997, 378: 669-678.
19. Kafri T, van Praag H, Gage F H, et al. Lentiviral vectors: regulated gene expression. Mol Ther, 2000, 1: 516-521.
20. Mark A K, Joseph C G, Luigi N. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med, 2001, 7: 33-40.